Skip to main content
. 2017 Jul 7;96(27):e7223. doi: 10.1097/MD.0000000000007223

Figure 2.

Figure 2

(A) Kaplan–Meier estimates of centrally assessed rPFS for East Asian patients and the overall study population (data cutoff, May 6, 2012). (B) Kaplan–Meier estimates of investigator-assessed rPFS for East Asian patients only (data cutoff, September 16, 2013). Dashed horizontal lines indicate median. Hazard ratios are based on unstratified Cox regression models with treatment as the only covariate, with values <1.00 favoring ENZA. CI = confidence interval, ENZA = enzalutamide, HR = hazard ratio, ITT = intent-to-treat, NYR = not yet reached, rPFS = radiographic progression-free survival.